Immatics
Dr. Kathy-Ann Secker-Grob is a highly skilled scientist currently working at Immatics as a Scientist in TCR Discovery - Preclinical Safety since October 2020. Prior to this role, Dr. Secker-Grob served as a Postdoctoral researcher at Universitätsklinikum Tübingen, focusing on cell therapeutic strategies in oncology and hematology from November 2016 to October 2020. This position involved extensive laboratory techniques and training, project management, and clinical trial data analysis. Dr. Secker-Grob earned a Ph.D. in Pharmacy from the University of Tübingen in 2020, following a Master of Science in Pharmaceutical Sciences and Technologies from the same institution in 2016. Additional experience includes pharmaceutical internships that provided strong foundations in patient consultation, quality management systems, and laboratory procedures.
This person is not in any teams
This person is not in any offices
Immatics
9 followers
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets.